Sveriges mest populära poddar
PharmaSource Podcast
VetenskapLife Science

GLP 1s and the Unintended Consequences of the $100 Billion Market

33 min•7 november 2024

GLP-1 drugs have become a game-changer in treating obesity and type 2 diabetes, forecast to reach a $100 billion market value by 2029.

However, their rapid rise raises important questions about resource allocation in pharmaceutical development and manufacturing, as well as affecting the dynamics between patients, healthcare providers, and biopharma.

In the latest episode of the PharmaSource podcast, Ben Locwin, Chief Scientist at Black Diamond Networks, explains that GLP-1 drugs represent a significant breakthrough in the treatment of obesity and diabetes and the unintended consequences they are bringing to the industry.

Read the article here

Fler avsnitt av PharmaSource Podcast

Visa alla avsnitt av PharmaSource Podcast
How the BMC Achieves Clinical-to-Commercial Quality Continuity Across Its Biologics CDMO Platform
•23 min
Digital Twins in Claude: How BioPharma Can Build Forecast and Supply Models
•30 min
Hybrid Synthesis is Redefining Peptide Manufacturing
•29 min
The Case for Strategic CDMO Partnerships Over Multi-Sourcing
•32 min
CDMO Consolidation “Inevitable” Without Business Model Shift, Warns Cell Therapy CEO
•47 min
Trump's Most-Favored-Nation Policy Is Forcing Europe's Pharma Industry to Reconsider Its Pricing Strategy
•27 min
How Europe’s Critical Medicines Act Could Reshape Generic Drug Supply Chains
•22 min
Reshoring America’s Critical Medicines: How the API Innovation Center Turns Idle Capacity Into a Drug Security Strategy
•36 min
How Radiopharmaceutical Supply Chains Win the Race Against Radioactive Decay: Insights from Daniel Rossetto, ARTBIO
•31 min
U.S. Vaccine Policy Shifts are Create a “Chilling” Effect on Global Manufacturing and Innovation
•35 min

PharmaSource Podcast med Life Science Networks finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.